With respect to targeting therapy at neutrophil-mediated inflammation, how does our understanding of the underlying pathobiology help select among treatment options that frequently require multi-modal approaches?

Professor Michael Loebinger, MA, FRCP, PhD

Director of the Lung DivisionaClinical Director of Laboratory MedicineaDeputy Medical DirectorConsultant Respiratory MedicineRoyal Brompton & Harefield HospitalsProfessor of Practice (Respiratory Medicine)National Heart and Lung InstituteImperial ...